UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 225

Sortiert nach

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2011-12, Vol.29 (35), p.4688-4695

2011

Link zum Volltext

Verfügbarkeit prüfen

Rho kinase inhibitors block melanoma cell migration and inhibit metastasis

Cancer research (Chicago, Ill.), 2015-06, Vol.75 (11), p.2272-2284

2015

Link zum Volltext

Verfügbarkeit prüfen

CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?

Nature reviews. Cancer, 2007-12, Vol.7 (12), p.925-936

2007

Link zum Volltext

Verfügbarkeit prüfen

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

Current opinion in pharmacology, 2008-08, Vol.8 (4), p.393-412

2008

Link zum Volltext

Verfügbarkeit prüfen

The ZO-1-Associated Y-Box Factor ZONAB Regulates Epithelial Cell Proliferation and Cell Density

The Journal of cell biology, 2003-02, Vol.160 (3), p.423-432

2003

Link zum Volltext

Verfügbarkeit prüfen

Anticancer therapy with checkpoint inhibitors: what, where and when?

Trends in pharmacological sciences (Regular ed.), 2011-05, Vol.32 (5), p.308-316

2011

Link zum Volltext

Verfügbarkeit prüfen

Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling

PloS one, 2012-01, Vol.7 (1), p.e28568

2012

Link zum Volltext

Verfügbarkeit prüfen

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor

Molecular oncology, 2018-03, Vol.12 (3), p.287-304

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy

Clinical cancer research, 2006-08, Vol.12 (15), p.4463-4468

2006

Link zum Volltext

Verfügbarkeit prüfen

Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery

Journal of medicinal chemistry, 2007-05, Vol.50 (10), p.2293-2296

2007

Link zum Volltext

Verfügbarkeit prüfen

Targeted Radiosensitization by the Chk1 Inhibitor SAR-020106

International journal of radiation oncology, biology, physics, 2013-03, Vol.85 (4), p.1110-1118

2013

Link zum Volltext

Verfügbarkeit prüfen

The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway

Cancer research (Chicago, Ill.), 2004, Vol.64 (1), p.262-272

2004

Link zum Volltext

Verfügbarkeit prüfen

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

Molecular cancer therapeutics, 2011-02, Vol.10 (2), p.360-371

2011

Link zum Volltext

Verfügbarkeit prüfen

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Drug discovery today, 2010-02, Vol.15 (3), p.88-97

2010

Link zum Volltext

Verfügbarkeit prüfen

A Structural Comparison of Inhibitor Binding to PKB, PKA and PKA-PKB Chimera

Journal of molecular biology, 2007-03, Vol.367 (3), p.882-894

2007

Link zum Volltext

Verfügbarkeit prüfen

Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2

PloS one, 2013-06, Vol.8 (6), p.e65689-e65689

2013

Link zum Volltext

Verfügbarkeit prüfen

CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells

Cancer research (Chicago, Ill.), 2020-04, Vol.80 (8), p.1735-1747

2020

Link zum Volltext

Verfügbarkeit prüfen

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

Clinical cancer research, 2005-07, Vol.11 (13), p.4875-4888

2005

Link zum Volltext

Verfügbarkeit prüfen

The Cyclin-Dependent Kinase Inhibitor Seliciclib (R-roscovitine; CYC202) Decreases the Expression of Mitotic Control Genes and Prevents Entry into Mitosis

Cell cycle (Georgetown, Tex.), 2007-12, Vol.6 (24), p.3114-3131

2007

Link zum Volltext

Verfügbarkeit prüfen

Selection of optimised ligands by fluorescence-activated bead sorting

Chemical science (Cambridge), 2023-09, Vol.14 (35), p.9517-9525

2023

Link zum Volltext

Verfügbarkeit prüfen

Rapid Evolution of 6-Phenylpurine Inhibitors of Protein Kinase B through Structure-Based Design

Journal of medicinal chemistry, 2007-05, Vol.50 (10), p.2289-2292

2007

Link zum Volltext

Verfügbarkeit prüfen

Anti-pancreatic lipase and anti-adipogenic effects of 5,7,3′,4′,5′-pentamethoxy and 6,2′,4′-trimethoxy flavone - An in vitro study

European journal of pharmacology, 2023-01, Vol.938, p.175445-175445, Article 175445

2023

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of action for the anti-obesogenic activities of phytochemicals

Phytochemistry (Oxford), 2020-12, Vol.180, p.112513-112513, Article 112513

2020

Link zum Volltext

Verfügbarkeit prüfen

Hydroxylated polymethoxyflavones reduce the activity of pancreatic lipase, inhibit adipogenesis and enhance lipolysis in 3T3-L1 mouse embryonic fibroblast cells

Chemico-biological interactions, 2023-07, Vol.379, p.110503-110503, Article 110503

2023

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors

Clinical cancer research, 2020-09, Vol.26 (18), p.4777-4784

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 225

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(211)
Mit Volltextzugriff
(207)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Rho kinase inhibitors block melanoma cell migration and inhibit metastasis

CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

The ZO-1-Associated Y-Box Factor ZONAB Regulates Epithelial Cell Proliferation and Cell Density

Anticancer therapy with checkpoint inhibitors: what, where and when?

Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor

Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy

Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery

Targeted Radiosensitization by the Chk1 Inhibitor SAR-020106

The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

A Structural Comparison of Inhibitor Binding to PKB, PKA and PKA-PKB Chimera

Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2

CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells

In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

The Cyclin-Dependent Kinase Inhibitor Seliciclib (R-roscovitine; CYC202) Decreases the Expression of Mitotic Control Genes and Prevents Entry into Mitosis

Selection of optimised ligands by fluorescence-activated bead sorting

Rapid Evolution of 6-Phenylpurine Inhibitors of Protein Kinase B through Structure-Based Design

Anti-pancreatic lipase and anti-adipogenic effects of 5,7,3′,4′,5′-pentamethoxy and 6,2′,4′-trimethoxy flavone - An in vitro study

Mechanisms of action for the anti-obesogenic activities of phytochemicals

Hydroxylated polymethoxyflavones reduce the activity of pancreatic lipase, inhibit adipogenesis and enhance lipolysis in 3T3-L1 mouse embryonic fibroblast cells

First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors

Suchergebnisse filtern